 SANTA MONICA, Calif., May 10, 2021 GLOBE NEWSWIRE -- BioVie Inc. NASDAQ: BIVI BioVie or Company, a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced amendments to certain terms for the previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., NeurMedix, a San Diego based privately held clinical-stage pharmaceutical company focused on novel therapeutic assets for the treatment of neurodegenerative and neurological disorders, as well as certain cancers. The pivotal Phase 3 trial in Alzheimers Disease is expected to begin this summer. 